Zhaoguo Chen

This inventor holds 9 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Medshine Discovery Inc., China Resources Pharmaceutical Holdings Company Limited, Cstone Pharmaceutical (Suzhou) Co., Ltd.. Active years: 2018-2026.

USPTO Granted Patents = 9 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 16)

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

6 out of 71

Medshine Discovery Inc.

patents

1 out of 2

China Resources Pharmaceutical Holdings Company Limited

patents

1 out of 1

Cstone Pharmaceutical (Suzhou) Co., Ltd.

patent

4. 1 out of 9

Cstone Pharmaceuticals

patents

5. 1 out of 1

Cstone Pharmaceuticals (Shanghai) Co., Ltd.

patent

6. 1 out of 1

Guizhou Inochini Technology Co., Ltd

patent

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583869 - Salt form and crystal form of A2A receptor antagonist and preparation method therefor (2026-03-24),

2. 12030897 - Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof (2024-07-09),

3. 11649239 - Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) (2023-05-16),

4. 11433053 - LSD1 inhibitor and preparation method and application thereof (2022-09-06),

5. 11377444 - Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors (2022-07-05),

6. 11155559 - Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity (2021-10-26),

7. 11117899 - [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor (2021-09-14),

8. 11046720 - Dimethylphosphine oxide compound (2021-06-29),

9. 9856264 - Isoquinolinesulfonyl derivative as RHO kinase inhibitor (2018-01-02),

Title: Zhaoguo Chen: Innovator in Pharmaceutical Chemistry

Introduction

Zhaoguo Chen is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of selective HER2 inhibitors. With a total of 9 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

One of Zhaoguo Chen's latest patents is focused on pyrrolo[2,1-f][1,2,4]triazine derivatives that serve as selective HER2 inhibitors. This invention relates to a group of compounds that can be utilized in the preparation of drugs aimed at inhibiting HER2. Specifically, it includes a compound represented by a specific formula, along with its isomers and pharmaceutically acceptable salts. Another notable patent involves a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound, which is disclosed along with its preparation method. This crystal form is intended for use in creating medicaments for treating A-receptor related diseases.

Career Highlights

Zhaoguo Chen has worked with several notable companies in the pharmaceutical industry. He has been associated with Medshine Discovery Inc. and China Resources Pharmaceutical Holdings Company Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Zhaoguo Chen has collaborated with various professionals in his field, including Shuhui Chen and Fang Liu. These collaborations have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Zhaoguo Chen is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug development. His contributions, particularly in the area of HER2 inhibitors, showcase his commitment to improving healthcare through innovation.